← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Biomarck Pharmaceuticals, Ltd
Durham, NC
$7,797,999
Total funding
4
Grants
Funding over time
peak $1.2M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,797,999 · 4
By mechanism
R44$7,298,940 · 1
R41$399,059 · 2
R43$100,000 · 1
Investigators at Biomarck Pharmaceuticals, Ltd
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Clinical Development a Therapeutic Agent for COPD$1,000,000
R44 · FY2008 · HL
Clinical Development of a Therapeutic Agent for COPD$1,000,000
R44 · FY2013 · HL
Clinical Development of a Therapeutic Agent for COPD$1,000,000
R44 · FY2014 · HL
Clinical Development of a Therapeutic Agent for COPD$1,000,000
R44 · FY2015 · HL
Clinical Development a Therapeutic Agent for COPD$1,000,000
R44 · FY2006 · HL
Clinical Development a Therapeutic Agent for COPD$990,000
R44 · FY2009 · HL
Preclinical Development of a Therapeutic Agent for COPD$632,540
R44 · FY2004 · HL
Preclinical Development of a Therapeutic Agent for COPD$596,400
R44 · FY2005 · HL
A novel therapeutic approach for Acute Lung Injury/ARDS$201,503
R41 · FY2014 · HL
MARCKS: A novel therapeutic target in uveitis$197,556
R41 · FY2019 · EY
Inhibition of Mucin Secretion in Murine Model of Asthma$100,000
R43 · FY2003 · HL
Clinical Development a Therapeutic Agent for COPD$80,000
R44 · FY2010 · HL